Intelligent Bio Solutions (INBS) Total Non-Current Liabilities (2023)
Intelligent Bio Solutions (INBS) recorded quarterly Total Non-Current Liabilities of $5.7 million in Q4 2023, down 14.81% quarter-over-quarter from $6.7 million in Q2 2023.
Intelligent Bio Solutions (INBS) Total Non-Current Liabilities (2023) Analysis & Trends
Intelligent Bio Solutions' Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $5.7 million for Q4 2023.
- In Q4 2023, Total Non-Current Liabilities changed N/A year-over-year to $5.7 million; the TTM figure through Dec 2023 stood at $5.7 million (changed N/A YoY), while the FY2023 annual figure was $6.7 million, changed N/A from the prior year.
- Total Non-Current Liabilities was $5.7 million for Q4 2023 at Intelligent Bio Solutions, down from $6.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $6.7 million in Q2 2023 to a low of $5.7 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 40.52 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 15.78 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 2.44 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 9.85 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 3.53 Bn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 3.47 Bn |
| 10 | Intelligent Bio Solutions | 12.67 Mn | 11.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 5.67 Mn |
| Jun 30, 2023 | 6.66 Mn |